Drug · Small Molecule

Ripretinib

CI-DRUG-00000523Explore in graph →NCIt C124067 CHEMBL4216467 CIViC Approved

Regulatory

Approvals (3)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory3 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as QINLOCK (DIN 02500833) under ATC L01EX19 RIPRETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 10, 2020	health-canada-dpd
EU EMA	—	Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	approved	Nov 18, 2021	ema
US FDA	—	QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ( 1 )	approved	May 15, 2020	openfda

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	4	2	3	10	3	CA, EU, US	May 15, 2020	2015-11

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 17 hours agoSource updated unknown

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KIT Mutation1
Ripretinib	Gastrointestinal Stromal Tumor

Clinical trials

Trials with this intervention (13)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–13 of 13 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05957367	A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies	recruiting	Phase 1 / Phase 2	94	Deciphera Pharmaceuticals, LLCINDUSTRY	9	Jul 23, 2026	clinicaltrials
NCT07618377	Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments	recruiting	Phase 1

Molecule

Record

Kind: Small Molecule
Mechanism: Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
Targets: 2 genes
UNII: 9XW757O13D
Aliases: 1-N'-[2,5-difluoro-4-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxyphenyl]-1-N'-phenylcyclopropane-1,1-dicarboxamide, DCC 2618, DCC-2618, DCC2618, KIT/PDGFR Inhibitor DCC-2618, Qinlock, QINLOCK, Ripretinib

Data updated 22 hours agoSource updated unknown

Identifiers

Codes (5)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01	Antineoplastic agents
ATC (WHO)	L01EX19	RIPRETINIB
DIN (Health Canada)